Drug
HMPL-306
HMPL-306 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/2)
Active Trials
1(25%)
Terminated
2(50%)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Terminated(2)
Other(1)
Detailed Status
Terminated2
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
0.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
recruiting125%
terminated250%
unknown125%
Recent Activity
1 active trials
Showing 4 of 4
terminatedphase_1
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
NCT04762602
terminatedphase_1
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
NCT04764474
recruitingphase_1
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
NCT07025018
unknownphase_1
A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
NCT04272957
Clinical Trials (4)
Showing 4 of 4 trials
NCT04762602Phase 1
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
NCT04764474Phase 1
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
NCT07025018Phase 1
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
NCT04272957Phase 1
A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4